FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid TumorsLeigh Marcus, Richard Pazdur, Steven J. Lemery et al.|Clinical Cancer Research|2019Cited by 1.2k
First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the IndicationSteven J. Lemery, Richard Pazdur, Patricia Keegan|New England Journal of Medicine|2017Cited by 657
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid TumorsLeigh Marcus, Steven J. Lemery, Lola A. Fashoyin‐Aje et al.|Clinical Cancer Research|2021Cited by 567